Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and Insulin Lispro.

Here the researchers performed a randomized open-label, three-way crossover, controlled multicenter study comparing GLU with ASP and insulin lispro (LIS).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Subjects with type 1 diabetes were allocated to one of three treatment orders-GLU-ASP-LIS, ASP-LIS-GLU, or LIS-GLU-ASP-with each insulin used for 13 weeks.

How the Study Was Run

The design is described as randomized, open-label, crossover, multicenter and pilot.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

Nothing was hidden in this open-label Insulin Aspart study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

The timeline in the abstract includes 13 weeks.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Diabetic Ketoacidosis, Glycated Hemoglobin, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Aspart and Insulin Lispro over 13 weeks.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page and the Insulin Lispro compound page, all human trials.